The global market for cough expectorant is expected to grow at a significant CAGR during the forecast period (2021-2027). Expectorants are medicinal substances that aid in the removal of mucus from the lungs, bronchi, and trachea. They work by improving mucus outflow from the lungs by thinning the mucus, as well as reducing respiratory tract irritation through the lubrication phenomenon. They also aid in the relief of chest congestion brought on by colds, allergies, and the flu.

Cough is the most common illness in the world, according to the World Health Organization. Reformulated medicines with improvised carriers or combinatorial treatments make up the majority of the new products. The market for expectorants is being driven by an increase in occurrences of dry cough, which causes dryness in the throat. However, the market for expectorants will be strengthened by the availability of economical OTC expectorants and the growing frequency of respiratory illnesses.

The rise in respiratory diseases is driving the global cough expectorant market growth. In addition, the growing elderly population and severe air pollution are propelling the need for cough expectorant. In addition, the market is projected to benefit from significant market potential in underdeveloped emerging nations, which will create attractive growth opportunities.

Furthermore, leading manufacturers are concentrating on developing cough syrup with various flavors and ease of administration for oral usage. Majority of the pediatric population is affected by the rising illness burden, since they have a lower degree of immunity than adults. Liquid dose formulations are preferred by the majority of pediatric patients. Cough expectorant demand is rising due to the availability of regularly monitored formulations, technical advancements in the field of medication delivery systems, and increased patient knowledge.

Vivimed Labs, a niche Specialty Chemicals and Pharmaceuticals company, received approval from CDSCO in November 2020 for Asko Expectorant, a combination therapy of Bromhexine HCI, Guaifenesin, and Menthol Expectorant to treat or prevent bronchospasm in patients with asthma, bronchitis, emphysema, and other lung diseases.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Type – Drug, OTC, Herbal

o By Route of Administration – Oral, Inhalational

o By End – User – Hospitals, SpecialityClinics

• Competitive Landscape: Boehringer Ingelheim International GmbH., ACADIA Pharmaceuticals Inc., Perrigo Company plc., Reckitt Benckiser Group plc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., and Aurobindo Pharma among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Cough Expectorant Market Report 

By Type

• Drug
• OTC
• Herbal

By Route of Administration

• Oral
• Inhalational

By End – User

• Hospitals
• Specialty Clinics

By Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa